NYSE American · TOVXHealthcarePharmaceuticals

Theriva Biologics news

$0.2100−3.00%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Theriva Biologics

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

GlobeNewswire Inc.Jun 11, 8:00 AM ET▲ Positive

Company announced positive Phase 1 clinical trial results showing prolonged overall survival in heavily pre-treated cancer patients, with biomarker data supporting the drug's mechanism of action. FDA alignment on Phase 3 trial design for pancreatic cancer indication further validates the therapeutic approach and suggests progress toward commercialization.

Also mentions TOVX

Articles that tag TOVX but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology